For Institutions
About
Fosun Pharma Seeks Approval for New Indication of Cancer Drug
Shanghai Fosun Pharmaceutical's subsidiary, Shanghai Zhaohui Pharmaceutical, has received approval from the National Medical Products Administration to begin Phase III clinical trials for a Ketoprofen Patch in China. This patch is intended for analgesic and anti-inflammatory uses. The approval is a significant step in the company's R&D efforts. The most recent analyst rating for Fosun Pharma's stock (HK:2196) is a Buy with a HK$35.30 price target.
